Physician profile
Michael Dale Fields
NPI 1699757237
$2,233.36
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $549 · 2021: $837 · 2022: $681 · 2023: $15.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.77 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.77 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $346.96 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $328.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $237.41 | 2020-2022 | |
| Abbvie INC. | $181.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $165.15 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $149.01 | 2019-2022 | |
| Althera Pharmaceuticals LLC | $144.97 | 2022 | |
| Intuity Medical INC | $115.74 | 2022 | |
| Eisai INC. | $113.41 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.10 | 2019 | |
| Amgen INC. | $94.85 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $57.52 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.91 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $34.24 | 2022 | |
| Biogen, INC. | $29.46 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.62 | 2020 | |
| Lilly USA, LLC | $13.09 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.37 | 2022 | |
| Genentech USA, INC. | $12.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.16 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.